The Regulatory Spotlight and Its Blind Spots
PFOA (perfluorooctanoic acid) and PFOS (perfluorooctane sulfonic acid) occupy the center of nearly every public conversation about PFAS contamination. They were among the first compounds identified in human blood at measurable concentrations, they were used at scale in consumer products and industrial processes for decades, and their toxicological profiles — linking exposure to cancer, immune suppression, thyroid disruption, and developmental harm — are among the most thoroughly documented in environmental health science. Regulatory focus on these two compounds is not arbitrary; it reflects the available evidence base.
But evidence availability is partly a function of where researchers looked. PFOA and PFOS were prioritized for study because they were detected first, in large amounts, in populations with known industrial exposure. The remaining 4,698+ compounds in the PFAS family were studied far less intensively — not because they posed no risk, but because the resources to characterize thousands of structurally related molecules did not exist when the regulatory framework was being built.
What the Other Compounds Are
The broader PFAS family includes short-chain perfluoroalkyl carboxylic acids (PFCAs) such as PFBA (C4), PFPeA (C5), and PFHxA (C6); short-chain perfluoroalkyl sulfonic acids (PFSAs) such as PFBS (C4) and PFHxS (C6); ultra-short compounds including trifluoroacetic acid (TFA, C3); fluorotelomer alcohols (FTOHs) and their transformation products; perfluoroalkyl sulfonamides (FASAs); polyfluoroalkyl phosphate esters (PAPs); and a growing class of ‘replacement PFAS’ including GenX (HFPO-DA), ADONA, and F-53B.
Many of these compounds are now detected in drinking water sources, agricultural soils, food packaging leachate, and human serum at concentrations that are not trivial. PFBS, for instance, has been detected in tap water samples across the United States at concentrations comparable to or exceeding those of PFOA in certain regions. Yet no standard point-of-use filter certification requires testing against PFBS.
Health Data for Non-Regulated PFAS
Epidemiological and toxicological data for non-PFOA/PFOS compounds are growing but remain incomplete. Animal studies indicate that PFBS causes thyroid disruption at relatively low doses. PFHxS has been associated with thyroid hormone changes and immune effects in human epidemiological studies. GenX, despite being positioned as a safer PFOA replacement, has been found to cause liver tumors in rodent studies and has been detected downstream of manufacturing facilities at concentrations that exceed health advisory levels.
The 2024 EPA MCL rule’s inclusion of PFNA, PFHxS, and GenX alongside PFOA and PFOS represents an acknowledgment that the regulatory perimeter needed to expand. The hazard index framework for mixtures recognizes that co-exposure to multiple PFAS compounds — even those individually below their MCLs — can produce cumulative health effects. These are meaningful advances. They are also steps in a much longer journey across thousands of compounds.
Implications for Filter Selection
A filter buyer evaluating a product certified to remove PFOA and PFOS at 99%+ efficiency is receiving accurate but deeply incomplete information. The same filter may remove PFBS at 15%, PFHxA at 25%, TFA at 0%, and GenX at 40–60% depending on carbon bed depth and contact time. None of these figures appear on the product label or in the NSF/ANSI 53 certification summary, because the certification does not require testing for those compounds.
The practical implication is that ‘PFOA/PFOS-certified’ filters may provide a false sense of security in communities or industrial settings where short-chain or replacement PFAS are the dominant contaminants — which, as legacy long-chain compounds are phased out, is increasingly the case. Addressing the other 4,698 compounds requires a different set of questions, different test protocols, and in some cases different treatment technologies.